Is PT-141 (Bremelanotide) safe?
Well-StudiedSide effects, risks, and safety considerations based on available research.
Research status
PT-141 (Bremelanotide) has a relatively strong evidence base including clinical trials in humans. This does not mean it is without risks, but its safety profile is better characterized than many other peptides.
Known concerns & side effects
- ⚠FDA approval is specifically for HSDD in premenopausal women — off-label use is not well-studied
- ⚠common side effects include nausea (40% of users), flushing, and headache
- ⚠can cause transient increases in blood pressure
- ⚠may cause skin hyperpigmentation with repeated use
- ⚠not to be used more than once in 24 hours or more than 8 times per month per labeling
- ⚠compounded versions are unregulated and may differ from the approved formulation
Use caution with
Frequently asked questions
Is PT-141 the same as Vyleesi?
Yes. Vyleesi is the brand name for bremelanotide (PT-141), FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 from peptide suppliers contains the same molecule but is not subject to the same manufacturing and purity standards.
Does PT-141 work for men?
PT-141 is not FDA approved for use in men. Some early studies explored its use for erectile dysfunction, but development for that indication was discontinued. Off-label male use lacks robust clinical evidence and should only be considered under physician supervision.
Full PT-141 (Bremelanotide) Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2025-03-21
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.